Bonnie Ramsey | Academic Influence

Bonnie Ramsey's AcademicInfluence.com Rankings

Bonnie Ramsey

Philosophy

#9451

World Rank

#13012

Historical Rank

#1766

USA Rank

Logic

#6426

World Rank

#7943

Historical Rank

#942

USA Rank

philosophy Degrees

Download Badge

Philosophy

Bonnie Ramsey's Degrees

Bachelors Biology University of Washington
Doctorate Medicine University of Washington

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2025

Why Is Bonnie Ramsey Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Bonnie W. Ramsey is the Endowed Chair in Cystic Fibrosis at the University of Washington School of Medicine and the director of the Center for Clinical and Translational Research at Seattle Children's Research Institute. Her research focuses on treatments for cystic fibrosis.

(See a Problem?)

Bonnie Ramsey's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. (2011) (1829)
Pathophysiology and management of pulmonary infections in cystic fibrosis. (2003) (1594)
Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. (1994) (1400)
Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. (2006) (1302)
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. (2015) (1178)
Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. (1999) (1094)
Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis (2002) (992)
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. (2019) (832)
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. (2010) (619)
Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. (2001) (597)
Management of pulmonary disease in patients with cystic fibrosis. (1996) (498)
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial (2019) (489)
Efficacy of aerosolized tobramycin in patients with cystic fibrosis. (1993) (444)
Microbiology of sputum from patients at cystic fibrosis centers in the United States. (1998) (430)
Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis * (2001) (411)
Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. (2014) (410)
Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa (2006) (384)
Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. (2004) (376)
Gender gap in cystic fibrosis mortality. (1997) (351)
Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis (1999) (326)
Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patients (2007) (318)
Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. (2003) (303)
Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. (2002) (291)
Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. (2003) (288)
Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. (1999) (284)
Defining a pulmonary exacerbation in cystic fibrosis. (2001) (276)
Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. (2006) (264)
Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. (1996) (262)
Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. (2007) (261)
Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression. (2009) (246)
A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. (2001) (232)
Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. (1993) (227)
Association between pulmonary function and sputum biomarkers in cystic fibrosis. (2007) (225)
Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. (1985) (224)
Outcome measures for clinical trials in cystic fibrosis. Summary of a Cystic Fibrosis Foundation consensus conference. (1994) (214)
Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. (2011) (204)
Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection (2013) (198)
Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. (2009) (194)
Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor. (2015) (191)
VX‐659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles (2018) (181)
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. (2015) (164)
Inhaled antibiotics for lower airway infections. (2014) (164)
Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis. (2013) (157)
Predictive value of oropharyngeal cultures for identifying lower airway bacteria in cystic fibrosis patients. (1991) (152)
Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis (1989) (151)
Impact of sinusitis in cystic fibrosis. (1992) (145)
Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. (1988) (136)
Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis (2004) (132)
Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management (2003) (128)
Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study. (1984) (128)
Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data. (2014) (123)
Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors. (1998) (121)
Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. (2016) (118)
A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group. (1997) (117)
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. (2009) (116)
Unique lipid a modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosis. (2007) (113)
Macromolecular mechanisms of sputum inhibition of tobramycin activity (1995) (112)
Comparison of a β-lactam alone versus β-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis (1999) (108)
Genome mosaicism is conserved but not unique in Pseudomonas aeruginosa isolates from the airways of young children with cystic fibrosis. (2003) (108)
Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum. (1983) (107)
Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes. (2014) (107)
The effect of respiratory viral infections on patients with cystic fibrosis. (1989) (104)
Nontuberculous mycobacterial disease in adult cystic fibrosis patients. (1993) (97)
Patient-reported respiratory symptoms in cystic fibrosis. (2009) (96)
Effect of nebulizer type and antibiotic concentration on device performance (1997) (96)
Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis (2007) (95)
Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: Results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis (2005) (93)
No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. (2007) (91)
Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis. (2007) (88)
Use of bacterial antigen detection in the diagnosis of pediatric lower respiratory tract infections. (1986) (85)
The Changing Face of Cystic Fibrosis (2020) (83)
Cystic fibrosis therapeutics: the road ahead. (2013) (83)
Home Monitoring of Patients with Cystic Fibrosis to Identify and Treat Acute Pulmonary Exacerbations. eICE Study Results (2017) (82)
Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function. (2011) (80)
Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes. (2021) (79)
Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort. (2012) (79)
Metagenomic evidence for taxonomic dysbiosis and functional imbalance in the gastrointestinal tracts of children with cystic fibrosis (2016) (75)
Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial (2018) (75)
Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis (2012) (74)
Future directions in early cystic fibrosis lung disease research: an NHLBI workshop report. (2012) (74)
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele (2021) (73)
Effects of Diagnosis by Newborn Screening for Cystic Fibrosis on Weight and Length in the First Year of Life (2017) (72)
Impact of Sustained Eradication of New Pseudomonas aeruginosa Infection on Long-term Outcomes in Cystic Fibrosis. (2015) (68)
Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis. (2001) (68)
Escherichia coli dysbiosis correlates with gastrointestinal dysfunction in children with cystic fibrosis. (2014) (67)
Advancing outcome measures for the new era of drug development in cystic fibrosis. (2007) (67)
Disease-specific reference equations for lung function in patients with cystic fibrosis. (2005) (66)
Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis (2007) (66)
Home nebulizer use among patients with cystic fibrosis. (1998) (64)
Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors (2015) (63)
Progress in cystic fibrosis and the CF Therapeutics Development Network (2012) (63)
Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects. (1994) (62)
Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles (2019) (61)
Baseline Characteristics and Factors Associated With Nutritional and Pulmonary Status at Enrollment in the Cystic Fibrosis EPIC Observational Cohort (2010) (60)
Pseudomonas aeruginosa phenotypes associated with eradication failure in children with cystic fibrosis. (2014) (58)
Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalating Study of Aerosolized Interferon Gamma‐1b in Patients With Mild to Moderate Cystic Fibrosis Lung Disease (2005) (57)
Nutritional effects of long-term gastrostomy feedings in children with cystic fibrosis. (1999) (56)
Use of ibuprofen to assess inflammatory biomarkers in induced sputum: Implications for clinical trials in cystic fibrosis. (2015) (55)
Clinical manifestations and treatment of pulmonary infections in cystic fibrosis. (1993) (51)
Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. (1999) (50)
Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis. (2016) (49)
Effects of repetitive use and cleaning techniques of disposable jet nebulizers on aerosol generation. (1998) (48)
Pharmacokinetics of ticarcillin in patients with cystic fibrosis: A controlled prospective study (1990) (46)
Disposition of drugs in cystic fibrosis. I. Sulfamethoxazole and trimethoprim (1991) (46)
Disposition of drugs in cystic fibrosis. IV. Mechanisms for enhanced renal clearance of ticarcillin (1993) (43)
The cystic fibrosis therapeutics development network (CF TDN): a paradigm of a clinical trials network for genetic and orphan diseases. (2002) (42)
Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: Results of a phase I multi‐center study (2001) (42)
Electron microprobe analysis of human labial gland secretory granules in cystic fibrosis. (1985) (42)
Maximal daily dose of pancreatic enzyme replacement therapy in infants with cystic fibrosis: a reconsideration. (2013) (41)
Islet Interleukin-1β Immunoreactivity Is an Early Feature of Cystic Fibrosis That May Contribute to β-Cell Failure (2018) (35)
Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1. (2019) (34)
Clinical trial participants compared with nonparticipants in cystic fibrosis. (2006) (33)
Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. (1997) (33)
Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial. (2013) (32)
Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial. (2013) (32)
Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis (2013) (31)
Nebulizer delivery of tobramycin to the lower respiratory tract (1994) (31)
A pipeline of therapies for cystic fibrosis. (2009) (30)
Research on cystic fibrosis: a journey from the Heart House. (1998) (29)
Update in Cystic Fibrosis 2014. (2015) (28)
New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator. (2016) (26)
Are Central Institutional Review Boards the Solution? The National Heart, Lung, and Blood Institute Working Group’s Report on Optimizing the IRB Process (2012) (25)
To cohort or not to cohort: how transmissible is Pseudomonas aeruginosa? (2002) (23)
Safety and efficacy of anti-pseudomonal therapy for early eradication of Pseudomonas: The epic study (2009) (22)
Disposition of drugs in cystic fibrosis. VI. In vivo activity of cytochrome P450 isoforms involved in the metabolism of (R)‐warfarin (including P450 3A4) is not enhanced in cystic fibrosis (1994) (22)
PHASE 3 EFFICACY AND SAFETY DATA FROM RANDOMIZED, MULTICENTER STUDY OF LIPOSOMAL AMIKACIN FOR INHALATION (ARIKACE) COMPARED WITH TOBI (R) IN CYSTIC FIBROSIS PATIENTS WITH CHRONIC INFECTION DUE TO PSEUDOMONAS AERUGINOSA (2013) (21)
Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in children with cystic fibrosis. (2014) (19)
Outcome measures for development of new therapies in cystic fibrosis: are we making progress and what are the next steps? (2007) (18)
Modifying disease in cystic fibrosis: current and future therapies on the horizon (2013) (18)
Reopening Schools Safely: The Case for Collaboration, Constructive Disruption of Pre-Coronavirus 2019 Expectations, and Creative Solutions (2020) (17)
AJRCCM: 100-Year Anniversary. Progress along the Pathway of Discovery Leading to Treatment and Cure of Cystic Fibrosis. (2017) (17)
TOBRAMYCIN SERUM CONCENTRATIONS AFTER AEROSOL AND ORAL ADMINISTRATION IN CYSTIC FIBROSIS (1995) (17)
Aerosol administration of antibiotics. (1995) (15)
Evolution of airway microbiology in the infant with cystic fibrosis: role of nonpseudomonal and pseudomonal pathogens. (1992) (15)
Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis (2010) (15)
Incidence and clinical significance of elevated liver function tests in cystic fibrosis clinical trials. (2013) (15)
Laboratory parameter profiles among patients with cystic fibrosis. (2007) (15)
Endobronchial Infection in Cystic Fibrosis (1989) (14)
Tezacaftor – Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe 508 del Alleles (2020) (14)
Pancreatic Enzyme Replacement Therapy Use in Infants With Cystic Fibrosis Diagnosed by Newborn Screening (2017) (14)
Early attained weight and length predict growth faltering better than velocity measures in infants with CF. (2014) (12)
Repeat administration of an adenovirus vector encoding cftr to the nasal epithelium of patients with cystic fibrosis (1996) (12)
Urinary metabolomics reveals unique metabolic signatures in infants with cystic fibrosis. (2019) (12)
Study design considerations for evaluating the efficacy and safety of pancreatic enzyme replacement therapy in patients with cystic fibrosis. (2013) (11)
Utilization of salivary concentrations of ciprofloxacin in subjects with cystic fibrosis (1997) (11)
Update in Cystic Fibrosis 2018. (2019) (10)
Use of lung imaging studies as outcome measures for development of new therapies in cystic fibrosis. (2007) (10)
Appropriate compensation of pediatric research participants: thoughts from an Institute of Medicine committee report. (2006) (10)
Evaluation Of Two Phase II Blinded and Placebo-Controlled Studies Of Nebulized Liposomal Amikacin (Arikace") In The Treatment Of Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection (2010) (9)
What is the role of upper airway bacterial cultures in patients with cystic fibrosis? (1996) (9)
Standardization of Research‐Quality Anthropometric Measurement of Infants and Implementation in a Multicenter Study (2015) (8)
Aerosol administration of antibiotics (1995) (7)
The Cystic Fibrosis Foundation Therapeutics Development Network: A National Effort by the Cystic Fibrosis Foundation to Build a Clinical Trials Network (2008) (7)
Probenecid pharmacokinetics in cystic fibrosis. (1991) (7)
AEROSOLIZED ANTIBIOTICS FOR BACTERIAL LOWER AIRWAY INFECTIONS : PRINCIPLES, EFFICACY, AND PITFALLS (1998) (7)
Randomized , Double-Blind , Placebo-Controlled , Dose-Escalating Study of Aerosolized Interferon Gamma-1 b in Patients With Mild to Moderate Cystic Fibrosis Lung Disease (2005) (6)
43 Patient-reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D-CFTR mutation (2012) (6)
WS6.3 Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D-CFTR mutation (2012) (6)
Pulmonary findings in infants with cystic fibrosis during the first year of life: Results from the Baby Observational and Nutrition Study (BONUS) cohort study (2019) (6)
Respiratory adverse event profiles in cystic fibrosis placebo subjects in short- and long-term inhaled therapy trials. (2006) (5)
Highly Effective Cystic Fibrosis Clinical Research Teams: Critical Success Factors (2014) (5)
WS01.3 Lumacaftor in combination with ivacaftor in patients with cystic fibrosis who are homozygous for the F508del-CFTR mutation (2015) (5)
Fibrosis: A Multicenter, Double-Blind, Placebo-Controlled Trial Cystic Transmembrane Regulator Gene Transfer to the Lungs of Patients With Repeated Adeno-Associated Virus Serotype 2 Aerosol-Mediated Cystic Fibrosis (2006) (5)
Not Quite the Bully in the Schoolyard: Staphylococcus aureus Can Survive and Coexist with Pseudomonas aeruginosa in the Cystic Fibrosis Lung (2020) (5)
Association Between Changes in Percent Predicted Fev1 and Incidence of Pulmonary Exacerbations, Including Those Requiring Hospitalization And/or IV Antibiotics, in Patients with Cf Treated with Lumacaftor in Combination with Ivacaftor (2015) (5)
Potassium release in labial glands from controls and patients with cystic fibrosis. (1989) (5)
Final results of a 14- and 28-day study of VX-770 in subjects with CF (2009) (4)
Response to: ‘Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?’ by Jones and Barry (2015) (4)
44 Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D-CFTR mutation (2012) (4)
Aerosolized Antibiotics for Bacterial Lower Airway Infections: Principles, Efficacy, and Pitfalls (1997) (4)
Membranous colitis in two cases of Hirschsprung's disease treated with large doses of antibiotics. (1955) (4)
Potentiating and correcting mutant CFTR in patients with cystic fibrosis (2014) (4)
Liver function in patients with cystic fibrosis ingesting fish oil. (1994) (4)
143 Lumacaftor/ivacaftor combination therapy in CF patients homozygous for F508del-CFTR with severe lung dysfunction (2015) (4)
Autonomic regulation of potassium release from human labial salivary glands in vitro. (1988) (4)
237. Survival and lung function during 2 years treatment with intermittent inhaled tobramycin in CF patients (1999) (3)
Effects of the CFTR potentiator, ivacaftor, in two phase 3 trials in subjects with CF who have the G551D-CFTR mutation (2012) (3)
Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials. (2023) (3)
Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. (2020) (3)
Aerosol administration of antibiotics in patients with cystic fibrosis (1994) (3)
Safety and Efficacy of Treatment with Lumacaftor in Combination with Ivacaftor in Patients with Cf Homozygous for F508Del-Cftr (2015) (3)
Caring for gender diverse youth with cystic fibrosis. (2020) (3)
Late-breaking abstract: VX-770, an investigational CFTR potentiator, in subjects with CF and the G551D mutation (2011) (3)
Cyclic nucleotide responses in control and cystic fibrosis labial glands. (1990) (2)
Most Short Children with Cystic Fibrosis Do Not Catch Up by Adulthood (2021) (2)
Remarkable progress toward new treatments for cystic fibrosis. (2014) (2)
PULMONARY, SLEEP, AND CRITICAL CARE UPDATE Update in Cystic Fibrosis 2014 (2015) (2)
Improvement in ion transport biomarkers and spirometry with the investigational CFTR potentiator VX-770 in subjects with cystic fibrosis and the G551D-CFTR mutation (2010) (2)
Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D-CFTR Mutation Treated With VX-770, An Investigational Oral Potentiator Of CFTR (2010) (2)
Comparative Monovalent Cation Transport in Neonatal and Adult Red Blood Cells (1984) (2)
Pulmonary Effects Of The Investigational CFTR Potentiator, Ivacaftor, In Two Phase 3 Trials In Subjects With CF Who Have The G551D-CFTR Mutation (2012) (2)
Impact of guideline-recommended dietitian assessments on weight gain in infants with cystic fibrosis. (2021) (2)
Gastrointestinal Factors Associated With Hospitalization in Infants With Cystic Fibrosis: Results From the Baby Observational and Nutrition Study (2021) (2)
Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup (2016) (1)
Diagnosis and Treatment of Cystic Fibrosis: A (Not-so) Simple Recessive Condition (2017) (1)
Reply to Shanthikumar et al.: Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis: Do the Benefits Outweigh the Harms? (2018) (1)
Impact of azithromycin on serum inflammatory markers in children with cystic fibrosis and new Pseudomonas. (2022) (1)
150 Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis (2013) (1)
Transforming the nutrition care model for infants with cystic fibrosis: A qualitative study of clinicians' perspectives (2023) (1)
Systemic Corticosteroids in the Management of Pediatric Cystic Fibrosis Pulmonary Exacerbations. (2022) (1)
Cystic Fibrosis: A Disease in Transformation, yet More Work to Be Done! (2022) (1)
Ivacaftor improved lung function in cystic fibrosis with G551d mutation (2012) (1)
Aerosol therapy in cystic fibrosis: DNase, tobramycin (1994) (1)
Access to CAR-T Cell Therapy in Underrepresented Populations: A Multicenter Cohort Study of Pediatric and Young Adult ALL Patients (2021) (1)
P279 Withdrawing existing chronic therapies in people with cystic fibrosis who benefit from highly effective CFTR modulator drugs (2019) (1)
THE PREVALENCE OF NEUTRALIZING ANTIBODY TO THE COMMON ADENOVIRUSES IN CHILDREN WITH CYSTIC FIBROSIS † 457 (1997) (0)
From the authors [4] (2006) (0)
SINUS DISEASE IN THE PATIENT WITH CYSTIC FIBROSIS (1994) (0)
Access to CAR T-cell Clinical Trials in Underrepresented Populations: a Multicenter Cohort Study of Pediatric and Young Adult ALL Patients. (2023) (0)
New and improved aminoglykosidformulierung as aerosol (1995) (0)
CHEST Ahead of the Curve Cystic Fibrosis Therapeutics The Road Ahead (2012) (0)
Tobramycin dosage recommendation in patients with cystic fibrosis (2005) (0)
New improved aminoglycoside for administration as an aerosol formulation. (1995) (0)
Transparency and diversity in cystic fibrosis research – Authors' reply (2020) (0)
185 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating or residual function mutation (2022) (0)
Association between stool consistency and clinical variables among infants with cystic fibrosis: Findings from the BONUS study. (2022) (0)
Cystic fibrosis : detection and monitoring of early lung disease 4655 (2011) (0)
New Therapeutic Approaches to Modulate and Correct CFTR (2017) (0)
Upper airway microbiota development in infants with cystic fibrosis diagnosed by newborn screen. (2023) (0)
65 Physician assessment of blinded adverse events in RCTs in cystic fibrosis (2017) (0)
Inhaled Tobramycin (TOBI ) A Review of its Use in the Management of Pseudomonas aeruginosa Infections in Patients with Cystic Fibrosis (2003) (0)
Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2 Through 5 Years with Cystic Fibrosis and at Least One F508del Allele. (2023) (0)

This paper list is powered by the following services:

Other Resources About Bonnie Ramsey

en.wikipedia.org

What Schools Are Affiliated With Bonnie Ramsey?

Bonnie Ramsey is affiliated with the following schools: